Cost of disease progression among US patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

Conclusion: Disease progression was associated with significant increases in HCRU and costs. Delays in progression were associated with lower cumulative healthcare costs. Earlier use of more clinically effective treatments to delay progression may reduce the economic burden among these patients.PMID:38647165 | DOI:10.57264/cer-2023-0166
Source: Journal of Comparative Effectiveness Research - Category: General Medicine Authors: Source Type: research